More than one, always more than one to address the real uncertainty.

The OHDSI study-a-thon group has a pre-print An international characterisation of patients hospitalised with COVID-19 and a comparison with those previously hospitalised with influenza.

What is encouraging with this one over yesterday’s study, is multiple data sources and almost too many co-authors to count (take that Nature’s editors).

So an opportunity to see the variation and some assurance that many eyes had an opportunity to see and question the protocol and the study work.

Results: 6,806 (US: 1,634, South Korea: 5,172) individuals hospitalised with COVID-19 were included. Patients in the US were majority male (VA OMOP: 94%, STARR-OMOP: 57%, CUIMC: 52%), but were majority female in HIRA (56%). Age profiles varied across data sources. Prevalence of asthma ranged from 7% to 14%, diabetes from 18% to 43%, and hypertensive disorder from 22% to 70% across data sources, while between 9% and 39% were taking drugs acting on the renin-angiotensin system in the 30 days prior to their hospitalisation. Compared to 52,422 individuals hospitalised with influenza, patients admitted with COVID-19 were more likely male, younger, and, in the US, had fewer comorbidities and lower medication use.

Now, it may be important to note that none of the authors had direct access to the very confidential patient data. They write analysis scripts which the data holders run (separately) and return data quality diagnostics and the summaries reported in the paper. Some ability to query the study here as well a access protocol and code.

Now this a live entity, the scripts can be run by any data holder at least after the data has been transformed into a standard format. Hopefully that can be done for the enterprise electronic health record (Sunrise Clinical Manager; Allscripts) reporting database from yesterday’s study.

If not, why not?